Figure 4.

HMGA2 is required for recognition of platinum-DNA lesions by XPC. (A) Survival of wild type (WT) and HMGA2 KO HCT116 cells cultured for 3 days in media containing oxaliplatin, or (B) cisplatin. (C) FRAP analysis showing XPC chromatin binding in GFP-XPC KI HCT116 cells WT or HMGA2 KO treated for 6 h with 400 μM of oxaliplatin, or (D) with 600 μM of cisplatin. Cell viability was measured using the CellTiter-Glo assay. Each dot in the FRAP graphs represents a single cell. A minimum of 20 cells was measured per experimental condition. Unpaired two-tailed parametric t-test with Welch's correction without assuming a consistent standard deviation was applied for comparison of groups in FRAP the analysis. Data in (A) and (B) represent mean +/− SEM of three independent experiments. Differences were calculated by the two-tailed t-test. *** P-value < 0.001.